• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    4/15/24 12:31:47 PM ET
    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ATHE alert in real time by email

    Gainers

    • Longeveron (NASDAQ:LGVN) stock moved upwards by 44.4% to $2.44 during Monday's regular session. The market value of their outstanding shares is at $7.7 million.
    • Mobile-health Network (NASDAQ:MNDR) shares rose 35.53% to $20.33. The company's market cap stands at $691.2 million.
    • Jaguar Health (NASDAQ:JAGX) shares moved upwards by 31.89% to $0.12. The company's market cap stands at $32.8 million.
    • Soligenix (NASDAQ:SNGX) stock increased by 30.35% to $0.5. The market value of their outstanding shares is at $5.2 million.
    • ProKidney (NASDAQ:PROK) stock increased by 26.33% to $2.21. The company's market cap stands at $136.2 million.
    • Organovo Holdings (NASDAQ:ONVO) shares moved upwards by 24.58% to $1.26. The market value of their outstanding shares is at $12.6 million.

    Losers

    • Marinus Pharma (NASDAQ:MRNS) shares fell 79.8% to $1.52 during Monday's regular session. The market value of their outstanding shares is at $83.4 million.
    • Alterity Therapeutics (NASDAQ:ATHE) stock decreased by 20.07% to $2.35. The company's market cap stands at $20.5 million.
    • BioSig Technologies (NASDAQ:BSGM) stock decreased by 18.76% to $1.1. The market value of their outstanding shares is at $10.3 million.
    • Rallybio (NASDAQ:RLYB) shares fell 18.16% to $1.8. The market value of their outstanding shares is at $74.6 million.
    • MSP Recovery (NASDAQ:LIFW) stock fell 17.42% to $0.94. The market value of their outstanding shares is at $13.9 million. As per the news, the Q4 earnings report came out today.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock declined by 17.15% to $1.16. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATHE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHE
    $BSGM
    $JAGX
    $LGVN

    CompanyDatePrice TargetRatingAnalyst
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    ProKidney Corp.
    $PROK
    6/30/2025$1.00Neutral → Underperform
    BofA Securities
    Rallybio Corporation
    $RLYB
    4/9/2025Buy → Neutral
    H.C. Wainwright
    Alterity Therapeutics Limited
    $ATHE
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    Alterity Therapeutics Limited
    $ATHE
    12/12/2024$8.00Buy
    Maxim Group
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    ProKidney Corp.
    $PROK
    9/30/2024Neutral
    JP Morgan
    Marinus Pharmaceuticals Inc.
    $MRNS
    9/23/2024$6.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Willard Stephen H was granted 400,000 shares and covered exercise/tax liability with 105,533 shares (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:59:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Willard Stephen H claimed no ownership of stock in the company (SEC Form 3)

    3 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:58:57 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Micek John was granted 7,377 shares, increasing direct ownership by 13,919% to 7,430 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    3/12/26 3:03:56 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Corp. downgraded by BofA Securities with a new price target

    BofA Securities downgraded ProKidney Corp. from Neutral to Underperform and set a new price target of $1.00

    6/30/25 7:57:01 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rallybio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Rallybio from Buy to Neutral

    4/9/25 8:36:28 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Jaguar Health Inc.

    PRE 14A - Jaguar Health, Inc. (0001585608) (Filer)

    3/13/26 4:59:50 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Longeveron Inc. (0001721484) (Filer)

    3/12/26 4:05:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/9/26 9:05:16 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Announces Closing of Private Placement of up to $30 Million

    $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,

    3/11/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Financials

    Live finance-specific insights

    View All

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

    Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030 Companies to hold joint conference call on March 2, 2026 at 8:30 AM ET Rallybio Corporation (NASDAQ:RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into

    3/2/26 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

    MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:   Conference Call Number: 1.877.407.0789Conference ID: 13755997   Call me™ Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available on the "Events & Presenta

    10/28/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $BSGM
    $JAGX
    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care